The proteasome as a target for protozoan parasites

Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders

(2019) Piotr Smolewski et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

(2019) Susan Wyllie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of novel Trypanosoma cruzi proteasome inhibitors using a luminescence-based high-throughput screening assay.

(2019) Filip Zmuda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability

(2019) Ena Ladi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors

(2019) Wenhu Zhan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study

(2019) William L Hamilton et al.   LANCET INFECTIOUS DISEASES

Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study

(2019) Rob W van der Pluijm et al.   LANCET INFECTIOUS DISEASES

Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents

(2019) Barbara H. Stokes et al.   PLoS Pathogens

The structure of the PA28–20S proteasome complex from Plasmodium falciparum and implications for proteostasis

(2019) Stanley C. Xie et al.   Nature Microbiology

Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem

(2018) Stephen J Rogerson et al.   LANCET INFECTIOUS DISEASES

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus

(2018) Tomonori Ishii et al.   Modern Rheumatology

Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance

(2018) Laura A. Kirkman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Uncovering the essential genes of the human malaria parasitePlasmodium falciparumby saturation mutagenesis

(2018) Min Zhang et al.   SCIENCE

Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics

(2018) Annie N. Cowell et al.   SCIENCE

Structural absorption by barbule microstructures of super black bird of paradise feathers

(2018) Dakota E. McCoy et al.   Nature Communications

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

(2018) Fabiana Alves et al.   CLINICAL MICROBIOLOGY REVIEWS

Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors

(2018) Euna Yoo et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome

(2018) Jessica L. Bridgford et al.   Nature Communications

Expanded Coverage of the 26S Proteasome Conformational Landscape Reveals Mechanisms of Peptidase Gating

(2018) Markus R. Eisele et al.   Cell Reports

Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome

(2018) Stanley C. Xie et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drug Discovery for Kinetoplastid Diseases: Future Directions

(2018) Srinivasa P. S. Rao et al.   ACS Infectious Diseases

Vaccines against malaria-still a long way to go

(2017) Kai Matuschewski   FEBS Journal

Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity

(2017) Gregory M. LaMonte et al.   JOURNAL OF MEDICINAL CHEMISTRY

New developments in anti-malarial target candidate and product profiles

(2017) Jeremy N. Burrows et al.   MALARIA JOURNAL

Proteasome inhibitors in cancer therapy

(2017) Elisabet E. Manasanch et al.   Nature Reviews Clinical Oncology

Protein Degradation Systems as Antimalarial Therapeutic Targets

(2017) Caroline L. Ng et al.   TRENDS IN PARASITOLOGY

A thiol probe for measuring unfolded protein load and proteostasis in cells

(2017) Moore Z. Chen et al.   Nature Communications

Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study

(2016) Chanaki Amaratunga et al.   LANCET INFECTIOUS DISEASES

Structure- and function-based design of Plasmodium-selective proteasome inhibitors

(2016) Hao Li et al.   NATURE

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

The inhibition mechanism of human 20Sproteasomes enables next-generation inhibitor design

(2016) Jil Schrader et al.   SCIENCE

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan

(2016) Roly Gosling et al.   PLOS MEDICINE

Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies

(2016) Peter J. Hotez et al.   PLoS Neglected Tropical Diseases

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study

(2015) Michele D Spring et al.   LANCET INFECTIOUS DISEASES

Overcoming neglect of kinetoplastid diseases

(2015) G. Bilbe   SCIENCE

Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib

(2015) Wayne Harshbarger et al.   STRUCTURE

Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum

(2015) Jigang Wang et al.   Nature Communications

Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance

(2015) Con Dogovski et al.   PLOS BIOLOGY

Directional Selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu Loci of Plasmodium falciparum in Kenyan Children Treated With ACT

(2014) Gisela Henriques et al.   JOURNAL OF INFECTIOUS DISEASES

Identification of Potent and Selective Non-covalent Inhibitors of the Plasmodium falciparum Proteasome

(2014) Hao Li et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

(2014) Shaji K Kumar et al.   LANCET ONCOLOGY

Broad-Spectrum Antimalarial Activity of Peptido Sulfonyl Fluorides, a New Class of Proteasome Inhibitors

(2013) Serena Tschan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Using Genetic Methods To Define the Targets of Compounds with Antimalarial Activity

(2013) Erika L. Flannery et al.   JOURNAL OF MEDICINAL CHEMISTRY

Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites

(2013) Paul P. Geurink et al.   JOURNAL OF MEDICINAL CHEMISTRY

Designing the next generation of medicines for malaria control and eradication

(2013) Jeremy N Burrows et al.   MALARIA JOURNAL

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

(2012) Eva M. Huber et al.   CELL

Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity

(2012) Hao Li et al.   CHEMISTRY & BIOLOGY

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

A framework for assessing the risk of resistance for anti-malarials in development

(2012) Xavier C Ding et al.   MALARIA JOURNAL

Should I Get Screened for Sleeping Sickness? A Qualitative Study in Kasai Province, Democratic Republic of Congo

(2012) Alain Mpanya et al.   PLoS Neglected Tropical Diseases

Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib

(2011) Anne C. Mirabella et al.   CHEMISTRY & BIOLOGY

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites

(2009) Matthew Britton et al.   CHEMISTRY & BIOLOGY

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon

(2008) Andrea Kreidenweiss et al.   MALARIA JOURNAL

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

(2008) Harald Noedl et al.   NEW ENGLAND JOURNAL OF MEDICINE